Drt2, established in 2002, is a pioneering pharmaceutical research and development company dedicated to addressing significant unmet medical needs in orphan endocrine diseases. Leveraging advanced cyclodextrin technology, we aim to develop innovative treatments that offer new hope to patients, their families, and healthcare providers. Drt2 is committed to leading the way in the orphan endocrine disease space, focusing on breakthrough solutions that improve lives and redefine care standards
